Thailand practice guideline for management of chronic hepatitis C 2018

Main Article Content

THASL Committee

Keywords

hepatitis C

Abstract

Chronic hepatitis C is one of the important cause of chronic liver diseases leading to cirrhosis and hepatocellular carcinoma worldwide. The prevalence of chronic hepatitis C in Thailand is about 1 - 5% where the prevalence is higher in the north and northeastern. Treatment of chronic hepatitis C has been developed and markedly improved in the last 3 decades. Since the advanced development of direct acting antiviral agent (DAA), treatment of chronic hepatitis C has been much improved not only in the efficacy but also tolerability and safety. IFN-free DAA treatment become a standard therapy in many country including Thailand. Due to fast development of HCV treatment strategies, Thailand Association for the Study of the Liver Disease has recurrently developed practice guideline for management of chronic hepatitis C in order to practically guide and to significantly improve HCV treatment in Thailand. The article reveals the detail of Thailand practice guideline for management of chronic hepatitis C 2018

Abstract 169 | PDF Downloads 249